Last reviewed · How we verify
NCT04128839
Impacts of Aronia on Inflammation and the Gut Microbiome
NA trial testing Aronia berry juice in Metabolic Syndrome in 40 participants. Completed in 27 December 2021.
30 September 2019
Quick facts
| Lead sponsor | Montana State University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 27 April 2019 |
| Primary completion | 30 September 2019 |
| Estimated completion | 27 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Aronia berry juice
- Sham comparator
Conditions studied
- Metabolic Syndrome — all drugs for Metabolic Syndrome →
- Inflammation — all drugs for Inflammation →
- Hypertriglyceridemia — all drugs for Hypertriglyceridemia →
- Obesity — all drugs for Obesity →
Sponsor
Montana State University
Who can join
Adults 18 to 55, any sex, with Metabolic Syndrome or Inflammation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal of this project is to determine the inflammation lowering impact of anthocyanin-rich Aronia berries. Inflammation is an underlying mechanism driving the development of several diseases. While an elevation in immune signals in the systemic circulation is commonly attributed to adipose tissue, inflammation is not present in all obese individuals. Adipose tissue must become inflamed, and the inflammation trigger may come from other sources. Microorganisms (microbiome), host tissues, and immune cells residing in the gastrointestinal tract (GIT) are a key source of pro-inflammatory signals that may cause the host organism to become inflamed. Anthocyanins are bioactive compounds with established anti-inflammatory and microbiome altering properties. We hypothesize that the GIT microbiome is a key determinant of host inflammation than can be manipulated by anthocyanins-rich berries to lower inflammation. We assembled a cohort of individuals, characterized their GIT microbiome and performed anthropometric measurements, basal measures of metabolism and metabolic health, and triglyceridemic, metabolomic, and inflammation responses to a high-fat meal challenge.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Determinants of the postprandial triglyceride response to a high-fat meal in healthy overweight and obese adults.
Wilson SM, Maes AP, Yeoman CJ, Walk ST, et al · · 2021 · cited 14× · PMID 34544430 · DOI 10.1186/s12944-021-01543-4 -
Metabolic impact of polyphenol-rich aronia fruit juice mediated by inflammation status of gut microbiome donors in humanized mouse model.
Wilson SMG, Peach JT, Fausset H, Miller ZT, et al · · 2023 · cited 7× · PMID 37727634 · DOI 10.3389/fnut.2023.1244692 -
Temporal metabolic response yields a dynamic biosignature of inflammation.
Peach JT, Wilson SM, Gunderson LD, Frothingham L, et al · · 2021 · cited 7× · PMID 34355150 · DOI 10.1016/j.isci.2021.102817 -
Determinants of the Postprandial Triglyceride Response to a High-fat Meal in Healthy Overweight and Obese Adults.
Wilson SM, Maes AP, Yeoman CJ, Walk ST, et al · · 2021 · DOI 10.21203/rs.3.rs-617713/v1
Verify or expand the search:
- PubMed search for NCT04128839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Syndrome
Currently open trials in the same condition.
- NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
- NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
- NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
Other Montana State University trials
Trials by the same sponsor.
- NCT07460973 — Nen ŨnkUmbi/EdaHiYedo Plus (We Are Here Now Plus): a Multi-level Intervention to Reduce Health Disparities Among America · NA · not yet recruiting
- NCT06938386 — Pilot Haskap Metabolite Timing Project · NA · active not recruiting
- NCT06878885 — Trauma and Cardiometabolic Health in an American Indian Community · NA · recruiting
- NCT05734014 — Strengthening Healthy Relationships Among Apsaalooke Youth · NA · completed
- NCT06298149 — Reach Through Equitable Implementation of Turtle Island Tales · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04128839 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Montana State University
- Last refreshed: 16 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04128839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing